Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Miller

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
Blood|February 21, 2004
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling ProjectLisa M Rimsza, Robin A Roberts, Thomas P Miller, et al.
Blood|October 22, 2005
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletionsLisa M Rimsza, Robin A Roberts, Elias Campo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001Daniel O Persky, Hongli Li, Deborah M Stephens, et al.
Haematologica|May 7, 2016
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Wael A Harb, Brian T Hill, et al.
The New England Journal of Medicine|November 1, 2013
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaPatrick J Stiff, Joseph M Unger, James R Cook, et al.
Blood|February 15, 2007
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survivalAdrian Wiestner, Mahsa Tehrani, Michael Chiorazzi, et al.
The Journal of Experimental Medicine|September 17, 2003
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaAndreas Rosenwald, George Wright, Karen Leroy, et al.
The New England Journal of Medicine|November 19, 2004
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cellsSandeep S Dave, George Wright, Bruce Tan, et al.
The New England Journal of Medicine|June 9, 2006
Molecular diagnosis of Burkitt's lymphomaSandeep S Dave, Kai Fu, George W Wright, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
Blood|February 21, 2004
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling ProjectLisa M Rimsza, Robin A Roberts, Thomas P Miller, et al.
Blood|October 22, 2005
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletionsLisa M Rimsza, Robin A Roberts, Elias Campo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001Daniel O Persky, Hongli Li, Deborah M Stephens, et al.
Haematologica|May 7, 2016
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Wael A Harb, Brian T Hill, et al.
The New England Journal of Medicine|November 1, 2013
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaPatrick J Stiff, Joseph M Unger, James R Cook, et al.
Blood|February 15, 2007
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survivalAdrian Wiestner, Mahsa Tehrani, Michael Chiorazzi, et al.
The Journal of Experimental Medicine|September 17, 2003
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaAndreas Rosenwald, George Wright, Karen Leroy, et al.
The New England Journal of Medicine|November 19, 2004
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cellsSandeep S Dave, George Wright, Bruce Tan, et al.
The New England Journal of Medicine|June 9, 2006
Molecular diagnosis of Burkitt's lymphomaSandeep S Dave, Kai Fu, George W Wright, et al.
Pageof 7